Based on 8 Wall Street analysts offering 12 month price targets for Bio-Techne in the last 3 months. The average price target is $81.63 with a high forecast of $95.00 and a low forecast of $65.00. The average price target represents a -2.60% change from the last price of $83.81.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"57":"$57","96":"$96","66.75":"$66.8","76.5":"$76.5","86.25":"$86.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$95.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":81.63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$81.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$65.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[57,66.75,76.5,86.25,96],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"Nov<br/>2023","9":"Feb<br/>2024","12":"May<br/>2024","25":"May<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.21,78.57846153846154,79.94692307692307,81.31538461538462,82.68384615384615,84.05230769230769,85.42076923076922,86.78923076923077,88.1576923076923,89.52615384615385,90.89461538461538,92.26307692307692,93.63153846153847,{"y":95,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.21,77.55,77.89,78.22999999999999,78.57,78.91,79.25,79.58999999999999,79.92999999999999,80.27,80.61,80.94999999999999,81.28999999999999,{"y":81.63,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,77.21,76.27076923076922,75.33153846153846,74.39230769230768,73.45307692307692,72.51384615384615,71.57461538461538,70.63538461538461,69.69615384615385,68.75692307692307,67.81769230769231,66.87846153846154,65.93923076923076,{"y":65,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":80.93,"date":1683849600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.62,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.44,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.8,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.48,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.99,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.51,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64.43,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.94,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.84,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.3,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.92,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.21,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$95.00

Average Price Target$81.63

Lowest Price Target$65.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

KeyBanc

xxxxxxxxxxxxx

Reiterated

05/02/24

xxxxxxxxxxxxxxxxxx

Benchmark Co.

xxxxxxxxxxxxx

Reiterated

05/02/24

xxxxxxxxxxxxxxxxxx

Scotiabank

xxxxxxxxxxxxx

Reiterated

05/02/24

xxxxxxxxxxxxxxxxxx

Stifel Nicolaus

xxxxxxxxxxxxx

Reiterated

05/02/24

xxxxxxxxxxxxxxxxxx

Robert W. Baird

xxxxxxxxxxxxx

Reiterated

05/01/24

xxxxxxxxxxxxxxxxxx

RBC Capital

xxxxxxxxxxxxx

Reiterated

05/01/24

xxxxxxxxxxxxxxxxxx

Leerink Partners

xxxxxxxxxxxxx

Assigned

05/01/24

xxxxxxxxxxxxxxxxxx

Deutsche Numis

xxxxxxxxxxxxx

Reiterated

04/18/24

xxxxxxxxxxxxxxxxxx

Stephens

xxxxxxxxxxxxx

Reiterated

02/02/24

xxxxxxxxxxxxxxxxxx

Craig-Hallum

xxxxxxxxxxxxx

Assigned

02/02/24

David Toung

Argus Research

$90.00

Buy

7.39%

Upside

Reiterated

01/04/24

Bio-Techne named 2024 Top Pick at Argus Bio-Techne named 2024 Top Pick at Argus

Douglas Harter

UBS

$80.00

Buy

-4.54%

Downside

Initiated

12/07/23

Bio-Techne initiated with a Buy at UBSBio-Techne initiated with a Buy at UBS

Timothy Daley

Wells Fargo

$66.00

Hold

-21.25%

Downside

Reiterated

11/14/23

Bio-Techne price target lowered to $66 from $90 at Wells FargoBio-Techne price target lowered to $66 from $90 at Wells Fargo

Patrick B Donnelly

Citi

$80.00

Buy

-4.54%

Downside

Reiterated

11/13/23

Positive Outlook for Bio-Techne Despite Challenges: An Analysis of Donnelly's Buy Rating Decision

Matt Larew

William Blair

―

Buy

―

Initiated

08/28/23

Bio-Techne initiated with an Outperform at William BlairBio-Techne initiated with an Outperform at William Blair

Best Analysts Covering Bio-Techne

Which Analyst Should I Follow If I Want to Buy TECH and Sell After:

1 Month

Catherine Ramsey SchulteRobert W. Baird

Success Rate

22/31 ratings generated profit

Average Return

+2.68%

reiterated a buy rating 18 days ago

Copying Catherine Ramsey Schulte's trades and holding each position for 1 Month would result in 70.97% of your transactions generating a profit, with an average return of +2.68% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

3 Months

Robert WassermanBenchmark Co.

Success Rate

7/10 ratings generated profit

Average Return

+4.84%

reiterated a buy rating 17 days ago

Copying Robert Wasserman's trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +4.84% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

1 Year

Catherine Ramsey SchulteRobert W. Baird

Success Rate

19/31 ratings generated profit

Average Return

+16.45%

reiterated a buy rating 18 days ago

Copying Catherine Ramsey Schulte's trades and holding each position for 1 Year would result in 61.29% of your transactions generating a profit, with an average return of +16.45% per trade.

2 Years

Robert WassermanBenchmark Co.

Success Rate

8/10 ratings generated profit

Average Return

+11.60%

reiterated a buy rating 17 days ago

Copying Robert Wasserman's trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +11.60% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TECH Analyst Recommendation Trends

Rating

Dec 23

Jan 24

Feb 24

Apr 24

May 24

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TECH has received 14 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. TECH average Analyst price target in the past 3 months is $81.63.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

TECH Financial Forecast

TECH Earnings Forecast

Next quarter’s earnings estimate for TECH is $0.50 with a range of $0.46 to $0.52. The previous quarter’s EPS was $0.48. TECH beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.30% of the time in the same period. In the last calendar year TECH has Underperformed its overall industry.

TECH Sales Forecast

Next quarter’s sales forecast for TECH is $306.34M with a range of $300.00M to $311.10M. The previous quarter’s sales results were $303.43M. TECH beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 46.17% of the time in the same period. In the last calendar year TECH has Underperformed its overall industry.

TECH Stock Forecast FAQ

What is TECH’s average 12-month price target, according to analysts?

Based on analyst ratings, Bio-Techne’s 12-month average price target is $81.63.

What is TECH’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for TECH, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TECH a Buy, Sell or Hold?

Bio-Techne has a conensus rating of Strong Buy which is based on 6 buy ratings, 2 hold ratings and 0 sell ratings.

What is Bio-Techne’s price target?

The average price target for Bio-Techne is $81.63. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $95.00 ,the lowest forecast is $65.00. The average price target represents -2.60% Decrease from the current price of $83.805.

What do analysts say about Bio-Techne?

Bio-Techne’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of TECH?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Bio-Techne (TECH) Stock Forecast & Price Target

TECH Analyst Ratings

TECH Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Bio-Techne

TECH Analyst Recommendation Trends

TECH Financial Forecast

TECH Earnings Forecast

TECH Sales Forecast

TECH Stock Forecast FAQ

Get More with TipRanks Premium

Detailed List of Analyst Forecasts